Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Kumar, Rajat  [Clear All Filters]
2018
Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating M-M, St Hilaire E, Kumar R, Delage R, et al. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leuk Res. 2018;74:21-41.
2019
Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, Michelis FV, Thyagu S, Kim DDong Hwan, Lipton JHoward, et al. Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. Eur J Haematol. 2019.
Salas MQueralt, Prem S, Atenafu EG, Law ADatt, Lam W, Al-Shaibani Z, Loach D, Kim DDong Hwan, Michelis FV, Lipton JHoward, et al. Reduced Intensity Allogeneic Stem Cell Transplant with Anti-Thymocyte globulin and Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia. Eur J Haematol. 2019.
Salas MQueralt, Lam W, Law ADatt, Kim DDong Hwan, Michelis FV, Loach D, Al-Shaibani Z, Lipton JHoward, Kumar R, Mattsson J, et al. Reduced Intensity Conditioning Allogeneic Transplant with Dual T-cell Depletion in Myelofibrosis. Eur J Haematol. 2019.
2020
Alotaibi AS, Prem S, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, et al. Fresh versus Frozen Allogeneic Peripheral Blood Stem Cell Grafts: a Successful Timely Option. Am J Hematol. 2020.
Salas MQueralt, Lam SChenc Wils, Pasic I, Gerbitz A, Michelis FV, Kim DDong Hwan, Al-Shaibani Z, Lipton JHoward, Mattsson J, Kumar R, et al. Less is More: Superior GVHD-Free/Relapse-Free Survival with Reduced Intensity Conditioning and Dual T-cell Depletion in AML. Biol Blood Marrow Transplant. 2020.
Nampoothiri RVasudevan, Chen S, Pasic I, Al-Shaibani Z, Lam W, Michelis FV, Kim DDong Hwan, Viswabandya A, Gerbitz A, Lipton JHoward, et al. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2020.
Alanazi W, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Mattsson J, et al. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Acta Haematol. 2020:1-8.
2021
Novitzky-Basso I, Remberger M, Chen C, Ellison C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, et al. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. Eur J Haematol. 2021.
Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DD, et al. ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2021.
Linn SMar, Nampoothiri RVasudevan, Chen C, Pasic I, Al-Shaibani Z, Lam W, Law ADatt, Michelis FV, Kim DDH, Gerbitz A, et al. Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. Hematol Oncol Stem Cell Ther. 2021.
Basso INovitzky, AlHayli S, Shin E, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, et al. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. Eur J Haematol. 2021.
2022
Nampoothiri RVasudevan, Pasic I, Law ADatt, Lam W, Chen C, Michelis FV, Kim DDong Hwan, Gerbitz A, Lipton JHoward, Kumar R, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Therapy-Related Hematologic Malignancies Developing After Multiple Myeloma. Eur J Haematol. 2022.
2023
Pereira MPinto, Remberger M, Chen C, Gerbitz A, Kim DDong Hwan, Kumar R, Lam W, Law ADatt, Lipton JH, Michelis FV, et al. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2023.
Al-Shaibani E, Chen S, Chen C, Pasic I, Michelis FV, Lam W, Law A, Novitzky-Basso I, Gerbitz A, Kim DD, et al. Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience. Ann Hematol. 2023.
Moya TAlfaro, Mattsson J, Remberger M, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Gerbitz A, et al. Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. Eur J Haematol. 2023.
Stavi V, Desai N, Michelis FV, Kim DDong Hwan, Kumar R, Lipton JHoward, Law ADatt. Late-onset Pneumocystis jirovecii pneumonia post-allogeneic stem cell transplantation after time-dependent discontinuation of prophylaxis. Eur J Haematol. 2023.
Nampoothiri RVasudevan, Tang K, Schuh A, Lam W, Maze D, Michelis FV, Chan S, Gupta V, Kim D, Kumar R, et al. Mutational Profile, Outcomes, and Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and Inconclusive Cytogenetic Analysis. Eur J Haematol. 2023.
Novitzky-Basso I, Patriquin C, Linn SMar, Chiarello C, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, et al. Propensity score matching analysis comparing the efficacy and steroid tapering benefit of extracorporeal photopheresis to best available therapy in third-line or beyond treatment for chronic GvHD. Transplant Cell Ther. 2023.
Linn SM, Novitzky-Basso I, Abduljalil O, Pasic I, Lam W, Law A, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, et al. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes. Hematol Oncol Stem Cell Ther. 2023;17(1):60-71.
Madsen K, Lee K, Chen S, Chen C, Law ADatt, Gerbitz A, Kumar R, Kim D, Lam W, Pasic I, et al. Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality. Support Care Cancer. 2023;31(10):564.
2024
Kim DDong Hwan, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RVasudevan, Lachance S, Deotare U, White J, Elemary M, et al. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. Curr Oncol. 2024;31(3):1426-1444.
Moya TAlfaro, Salas MQueralt, Carreira ASantos, Atenafu EG, Law ADatt, Lam W, Pasic I, Kim DDong Hwan, Michelis FV, Basso INovitzky, et al. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies. Bone Marrow Transplant. 2024.
Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi J-M, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, et al. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024.
Stavi V, Khaire N, Lipton JH, Kumar R. Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia-Single-Centre Experience. Curr Oncol. 2024;31(3):1246-1252.